Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis

By News Health
2 months Ago

(MedPage Today) — SAN FRANCISCO — The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed.
The trial tested two doses of…

Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118269

Author :

Publish date : 2025-11-01 20:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Supplement Yanked Over Suicide Risk; 'Dilbert' Creator Dies; Full-Body Scan Lawsuit

More People Survive Cancer, Report Shows

Are Cardiologists Overlooking Substance Use Risk?

'It's life-changing. I can see my child grow up'

Sleeping With the Light on May Increase Heart Disease Risk

What Do the New VCID Guidelines Mean for Clinical Practice?